Second phase I trial of ORADUR-ADHD.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2013
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 01 Aug 2013 Methylphenidate was disclosed as an agent evaluated in this trial. Methylphenidate is the lead agent in the ORADUR-ADHD programme.
- 04 Nov 2011 Status changed from planning to completed.
- 01 Jun 2011 New trial record